ReviewActa pharmaceutica Sinica. B2021
Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines.
Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Ginkgolide B-cyclodextrin inclusion complexes: an encapsulation strategy for improved solubility and aerosol inhalation therapy in bronchial asthma.Drug delivery and translational research · 2026Article
- Advances in Formulation and Technological Strategies for Montelukast Pulmonary Delivery.ACS omega · 2026Review
- Pulmonary Drug Delivery in the Era of Nanomedicine: From Biological Barriers to Artificial Intelligence-Driven Optimization.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Analytical investigation of metal distribution from e-cigarette aerosols to lung deposition using multi-platform mass spectrometry.Analytical and bioanalytical chemistry · 2026Article
- Inhalational therapy of pulmonary infectionActa pharmaceutica Sinica. B · 2026Article
- Inhalable Therapeutics in Lung Cancer: Overcoming Barriers for Effective Treatment.AAPS PharmSciTech · 2026Review
- Engineered mucus-tethering bispecific nanobodies enhance mucosal immunity against respiratory pathogens.Nature nanotechnology · 2026Article
- Polydopamine-polyethylene glycol-liproxstatin-1 nanoparticles inhibit ferroptosis for enhanced treatment of neutrophilic asthma.Frontiers in pharmacology · 2026Article
- Inhalable extracellular vesicles as cell-free therapeutics for chronic respiratory disease.Frontiers in bioengineering and biotechnology · 2026Review
- Pseudoginsenoside-F11: a comprehensive review of chemical structure, pharmacological activities, pharmacokinetics, and therapeutic potential.Frontiers in pharmacology · 2026Review
- Inhalable Nanocrystal-in-Microparticle of Linezolid in Pulmonary Tuberculosis.International journal of nanomedicine · 2026Article
- Lipid Co-Loaded with PGRN and NATA Demonstrated Significantly Enhanced Antifungal and Anti-Inflammatory Activities in the Treatment of Fungal Keratitis.International journal of nanomedicine · 2026Article
- Cyclodextrin-Based Nanotransporters as a Versatile Tool to Manage Oxidative Stress-Induced Lung Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Exploring the influence of vaping on the pharmacokinetic fate of inhaled therapeutics.Archives of toxicology · 2025Review
- Exploring the Potential of PLGA Nanoparticles for Enhancing Pulmonary Drug Delivery.Molecular pharmaceutics · 2025Review
- Mechanistic Analysis of Fluid Dynamics and Multifactorial Impact Mechanisms in Inhaled Pharmaceutical Deposition for Chronic Respiratory Diseases.Bioengineering (Basel, Switzerland) · 2025Article
- Formulation and In-Vitro Testing of Nebulized Camostat Mesylate Loaded Nanoliposomes for the Treatment of SARS-CoV- 2 Infection.AAPS PharmSciTech · 2025Article
- Solubilising and Aerosolising Cannabidiol Using Methyl β-Cyclodextrin and Human Serum Albumin.AAPS PharmSciTech · 2025Article
- Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery.CPT: pharmacometrics & systems pharmacology · 2025Article
- Ceftriaxone-Loaded Liposomal Nanoparticles for Pulmonary Delivery Against Lower Respiratory Tract Infections: Development and Characterization.Pharmaceuticals (Basel, Switzerland) · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma, chronic obstructive pulmonary diseases and respiratory infections, and systemic diseases such as diabetes. Most inhaled medicines could be cleared rapidly from the lungs and their therapeutic effects are transit. The inhaled medicines with extended pulmonary exposure may not only improve the patient compliance by reducing the frequency of drug administration, but also enhance the clinical benefits to the patients with improved therapeutic outcomes. This article systematically reviews the physical and chemical strategies to extend the pulmonary exposure of the inhaled medicines. It starts with an introduction of various physiological and pathophysiological barriers for designing inhaled medicines with extended lung exposure, which is followed by recent advances in various strategies to overcome these barriers. Finally, the applications of the inhaled medicines with extended lung exposure for the treatment of various diseases and the safety concerns associated to various strategies to extend the pulmonary exposure of the inhaled medicines are summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.